Shandong Zibo Xincat Pharmaceutical Co., Ltd.

Primary objective: To evaluate the efficacy of OAB-14 dry suspension compared with placebo in controlling the overall progression of the disease in patients with Alzheimer's disease; Key secondary objective: To evaluate the efficacy of OAB-14 dry suspension compared with placebo in controlling the progression of the disease in patients with Alzheimer's disease. Secondary objectives: To evaluate the efficacy of OAB-14 dry suspension in improving cognitive and/or functional decline in patients with Alzheimer's disease compared with placebo; To evaluate the efficacy of OAB-14 dry suspension in reducing amyloid plaques in the brain compared with placebo; To evaluate the efficacy of OAB-14 dry suspension in improving the behavior of patients with Alzheimer's disease compared with placebo; To evaluate the safety and tolerability of OAB-14 dry suspension; To evaluate the pharmacokinetic characteristics of OAB-14 dry suspension in patients with Alzheimer's disease; Exploratory objectives: To observe the concentration of OAB-14 in cerebrospinal fluid after oral administration of OAB-14 dry suspension; To evaluate the effect of OAB-14 dry suspension on the content of biomarkers in cerebrospinal fluid compared with placebo; To evaluate the effect of OAB-14 dry suspension on the content of biomarkers in plasma compared with placebo; To evaluate the efficacy of OAB-14 dry suspension in improving neuronal damage in the brain compared with placebo

Main research purpose: This study aims to study the pharmacokinetic characteristics of azithromycin tablets (0.25g) produced by Shandong Zibo Xinda Pharmaceutical Co., Ltd. after single oral administration on an empty stomach and after meals; using azithromycin tablets (Zithromax, 0.25g) produced by Pfizer Pharmaceuticals Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and evaluate the human bioequivalence of the two preparations.

This study aimed to investigate the pharmacokinetic characteristics of donepezil hydrochloride orodisintegrating tablets (5 mg) produced by Shandong Zibo Xinda Pharmaceutical Co., Ltd. in healthy study participants after single fasting and postprandial oral administration; using donepezil hydrochloride orodisintegrating tablets (Aricept® D, 5 mg) produced by Eisai Co., Ltd. as the reference preparation, to compare the pharmacokinetic parameters Cmax and AUC0-72 of the two preparations, to evaluate the bioequivalence of the two preparations in humans, and to observe the safety of the two preparations in healthy study participants.